Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJ. Guigay, Franck Darloy, Olivier Capitain et al.|The Lancet Oncology|2021Cited by 231
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckKevin J. Harrington, Robert I. Haddad, Robert L. Ferris et al.|JAMA Oncology|2023Cited by 73
Flap delineation guidelines in postoperative head and neck radiation therapy for head and neck cancersJennifer Le Guévelou, Juliette Thariat, Vianney Bastit et al.|Radiotherapy and Oncology|2020Cited by 25
Practical contouring guidelines with an MR-based atlas of brainstem structures involved in radiation-induced nausea and vomitingArnaud Beddok, Juliette Thariat, Jean Faivre et al.|Radiotherapy and Oncology|2018Cited by 13